Sopharma AD

Warsaw Stock Exchange SPH.WA

Sopharma AD Price to Earnings Ratio (P/E) on January 13, 2025

Sopharma AD Price to Earnings Ratio (P/E) is NA on January 13, 2025, a NA change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Sopharma AD 52-week high Price to Earnings Ratio (P/E) is NA on January 13, 2025, which is NA below the current Price to Earnings Ratio (P/E).
  • Sopharma AD 52-week low Price to Earnings Ratio (P/E) is NA on January 13, 2025, which is NA below the current Price to Earnings Ratio (P/E).
  • Sopharma AD average Price to Earnings Ratio (P/E) for the last 52 weeks is NA.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
Warsaw Stock Exchange: SPH.WA

Sopharma AD

CEO Mr. Ognian Ivanov Donev D.Sc. (Econ.), Ph.D.
IPO Date Nov. 1, 2011
Location Bulgaria
Headquarters 16 Iliensko shosse street
Employees 4,896
Sector Health Care
Industries
Description

Sopharma AD researches and develops, produces, and trades in medicinal substances, finished drug forms, veterinary vaccines, infusion solutions, and plastic medical disposable products for human and veterinary medicine, and food supplements in Bulgaria and internationally. It offers products in various therapeutic areas, such as cardiology, gastroenterology, pain management, cough and cold, immunology and dermatology, respiratory and asthma, neurology and psychiatry, urology, and gynecology. The company's products comprise Carsil to treat gastroenterological disorders; Tempalgin, an analgesic; Tabex, a plant-based drug used for smoking secession; Tribestan, a plant-based drug used for stimulation of functions of the sexual system; Broncholytin, which is used to suppress cough; Analgin, a generic analgesic; Nivalin, a plant-based product used for diseases of the peripheral nervous system; and Methylprednisolon, a general medicine for cases of severe allergies and life-threatening conditions. It also trades in food supplements; provides secondary packaging services for pharmaceutical products and real estate leases; trades, transports, and packages radioactive materials and nuclear equipment for medicinal use, household electronics, and electrical equipment; and purchases, collects, grows, produces, and trades in herbs and medicinal plants. In addition, the company engages in the retail trade of medicinal products and medical equipment; production of non-medicinal, and other products; and franchising, know-how, and rental of properties, as well as in trading, consulting, and other activities. Further, it offers market and public opinion research services; and engages in non-pharma activities, such as veterinary vaccines, infusion solutions. Sopharma AD was founded in 1933 and is headquartered in Sofia, Bulgaria.

Similar companies

MLG.WA

MLP Group S.A.

USD 17.28

1.31%

PCR.WA

PCC Rokita SA

USD 17.25

0.74%

ENA.WA

ENEA S.A.

USD 3.21

0.07%

CIG.WA

CI Games S.A.

USD 0.36

-0.59%

StockViz Staff

January 15, 2025

Any question? Send us an email